Björn‐Erik Roos

2.0k total citations · 1 hit paper
35 papers, 1.6k citations indexed

About

Björn‐Erik Roos is a scholar working on Cellular and Molecular Neuroscience, Neurology and Psychiatry and Mental health. According to data from OpenAlex, Björn‐Erik Roos has authored 35 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cellular and Molecular Neuroscience, 6 papers in Neurology and 6 papers in Psychiatry and Mental health. Recurrent topics in Björn‐Erik Roos's work include Neuroscience and Neuropharmacology Research (13 papers), Neurotransmitter Receptor Influence on Behavior (6 papers) and Amino Acid Enzymes and Metabolism (4 papers). Björn‐Erik Roos is often cited by papers focused on Neuroscience and Neuropharmacology Research (13 papers), Neurotransmitter Receptor Influence on Behavior (6 papers) and Amino Acid Enzymes and Metabolism (4 papers). Björn‐Erik Roos collaborates with scholars based in Sweden and United States. Björn‐Erik Roos's co-authors include Bengt Werdinius, Nils‐Erik Andén, Barbro Johansson, Barbro B. Johansson, Torgny Persson, Hugo Andersson, G. Steg, Ragnar Norrby, Erik Lycke and Yrjö O. Alanen and has published in prestigious journals such as The British Journal of Psychiatry, Biochemical Pharmacology and Life Sciences.

In The Last Decade

Björn‐Erik Roos

32 papers receiving 1.4k citations

Hit Papers

On the occurrence of homovanillic acid in brain and cereb... 1963 2026 1984 2005 1963 100 200 300

Peers

Björn‐Erik Roos
R. W. Colburn United States
T. B. B. Crawford United Kingdom
H. H. Keller Switzerland
Merton Sandler United Kingdom
M. Da Prada Switzerland
Edward G. Shaskan United States
A. T. B. Moir United Kingdom
Donald F. Bogdanski United States
Björn‐Erik Roos
Citations per year, relative to Björn‐Erik Roos Björn‐Erik Roos (= 1×) peers Bengt Werdinius

Countries citing papers authored by Björn‐Erik Roos

Since Specialization
Citations

This map shows the geographic impact of Björn‐Erik Roos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Björn‐Erik Roos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Björn‐Erik Roos more than expected).

Fields of papers citing papers by Björn‐Erik Roos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Björn‐Erik Roos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Björn‐Erik Roos. The network helps show where Björn‐Erik Roos may publish in the future.

Co-authorship network of co-authors of Björn‐Erik Roos

This figure shows the co-authorship network connecting the top 25 collaborators of Björn‐Erik Roos. A scholar is included among the top collaborators of Björn‐Erik Roos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Björn‐Erik Roos. Björn‐Erik Roos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Holmgren, Sven, et al.. (1983). The anorectic bulimic conflict. An alternative diagnostic approach to anorexia nervosa and bulimia. International Journal of Eating Disorders. 2(2). 3–14. 30 indexed citations
2.
Johansson, Barbro B. & Björn‐Erik Roos. (1975). CONCENTRATIONS OF MONOAMINE METABOLITES IN HUMAN LUMBAR AND CISTERNAL CEREBROSPINAL FLUID. Acta Neurologica Scandinavica. 52(2). 137–144. 24 indexed citations
3.
Ahlström, Ulf, Karl‐Erik Kahnberg, & Björn‐Erik Roos. (1974). Pentazocine and Aspirin for Pain Following Oral Surgery. Acta Pharmacologica et Toxicologica. 35(4). 325–336. 16 indexed citations
4.
Roos, Björn‐Erik. (1974). Catecholamine metabolites in CSF. Biochemical Pharmacology. 23. 873–874. 2 indexed citations
5.
Essen, Claes von & Björn‐Erik Roos. (1974). Further Evidence for the Existence of Specific Dopamine Receptors in the Cerebral Vascular Bed of the Dog. Acta Pharmacologica et Toxicologica. 35(5). 433–435. 9 indexed citations
6.
Lycke, Erik, Ragnar Norrby, & Björn‐Erik Roos. (1974). A Serological Study on Mentally Ill Patients. The British Journal of Psychiatry. 124(580). 273–279. 84 indexed citations
7.
Andersson, Hugo, Claes von Essen, & Björn‐Erik Roos. (1973). 5‐Hydroxyindole Acetic Acid and Homovanillic Acid in Cerebrospinal Fluid after Intrathecal and Intravenous Administration of Probenecid to Normal and Hydrocephalic Dogs. Acta Pharmacologica et Toxicologica. 32(1-2). 139–147. 6 indexed citations
8.
Carlsson, Arvid, et al.. (1973). Potentiering Av Neuroleptika Med Synteshämmaren α-Metyltyrosin Vid Behandling Av Kronisk Schizofreni. Nordisk Psykiatrisk Tidsskrift. 27(6). 420–421. 1 indexed citations
9.
Rimón, Ranan, Björn‐Erik Roos, Viljo Räkköläinen, & Yrjö O. Alanen. (1971). The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. Journal of Psychosomatic Research. 15(3). 375–378. 44 indexed citations
10.
Andersson, Hugo & Björn‐Erik Roos. (1968). The effect of probenecid on the elimination from CSF of intraventricularly injected 5-hydroxyindoleacetic acid in normal and hydrocephalic dogs. Journal of Pharmacy and Pharmacology. 20(11). 879–881. 14 indexed citations
11.
Andersson, Hugo & Björn‐Erik Roos. (1968). 5‐Hydroxyindoleacetic Acid in Cerebrospinal Fluid after Administration of 5‐Hydroxytryptophan I. Acta Pharmacologica et Toxicologica. 26(4). 293–297. 30 indexed citations
12.
Johansson, Barbro & Björn‐Erik Roos. (1967). 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sciences. 6(13). 1449–1454. 107 indexed citations
13.
Häggendal, Jan, Margit Lindqvist, & Björn‐Erik Roos. (1967). Further Studies on Monoamine Metabolism and Behaviour in Rabbits Chronically Treated with Reserpine. Acta Physiologica Scandinavica. 69(1-2). 95–101. 11 indexed citations
14.
Andén, Nils‐Erik, Tor Magnusson, Björn‐Erik Roos, & Bengt Werdinius. (1965). 5-Hydroxyindoleacetic acid of rabbit spinal cord normally and after transection.. PubMed. 64(3). 193–6. 8 indexed citations
16.
Roos, Björn‐Erik. (1964). THE EFFECT OF RESERPINE, CHLORPROMAZINE AND HALOPERIDOL ON THE MONOAMINES IN CENTRAL NERVOUS SYSTEM. Acta Psychiatrica Scandinavica. 39(S180). 421–422. 2 indexed citations
17.
Roos, Björn‐Erik & Bengt Werdinius. (1963). The effect of α -methyl dopa on the metabolism of 5-hydroxytryptamine in brain. Life Sciences. 2(2). 92–96. 30 indexed citations
18.
Andén, Nils‐Erik, Björn‐Erik Roos, & Bengt Werdinius. (1963). On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sciences. 2(7). 448–458. 357 indexed citations breakdown →
19.
Roos, Björn‐Erik. (1962). On the occurrence and distribution of 5-hydroxyindoleacetic acid in brain. Life Sciences. 1(1). 25–27. 41 indexed citations
20.
Roos, Björn‐Erik & Bengt Werdinius. (1962). Effect of reserpine on the level of 5-hydroxyindoleacetic acid in brain. Life Sciences. 1(3). 105–107. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026